当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • Jゲートを開く
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Studying Cost as a Factor in the Choice between Quality and Quantity of Life amongst Patients with Cancer and their Caregivers at a Cancer Centre in Singapore

Keson Tay, Lee Jiayu Rachel, Sim Shin Wei Dorsett, Sumytra Menon, Ravindran Kanesvaran, Rukshini Puvanendran, Lalit Kumar Radha Krishna

Background: Treatment costs and sociocultural concerns play a significant role in decisions regarding Quantity of Life (QuoL) options that seek to prolong life, such as chemotherapy, or a Quality of Life (QoL) approach where the patient refuses available treatments such as chemotherapy in favour of maximizing comfort and quality of life at the end of life in Singapore. Deciphering the reasons behind such care decisions is often difficult because of local social taboos regarding discussions about death and dying. Objectives: To scrutinize the rationale behind QuoL and QoL within the Singapore context and delineate the impact of cost upon such decisions. Methods: To overcome local sociocultural taboos about discussing death and dying with patients, participants watched a video vignette of a family discussing treatment options for their mother (Mrs Tan) who was recently diagnosed with terminal cancer. Participants were asked what advice they would offer Mrs Tan regarding her treatment plans in the face of a poor prognosis, incurable cancer and costly treatment. Participants were then asked what their advice would be when the costs of treatment was covered by the patient’s insurance policy. Their responses were evaluated using Grounded Theory analysis. Setting/Subjects: 132 oncology patients and their caregivers were recruited from an ambulatory treatment unit at a tertiary oncology centre. Results: 63 (47.7%) of 132 participants advised Mrs Tan to opt for the QoL approach but when treatment costs were covered by insurance, only 5 (3.8%) of 132 participants chose QoL, whilst 108 (81.8%) participants chose QuoL options. Conclusion: Whilst cost is a significant factor in end of life decision making, strong sociocultural influences that perceive QoL approaches as ‘giving up’ ultimately determines the course of care.